To our knowledge, the present study represents the first use of the CRISPR-Cas9 genome editing tool to perform MMP-9 knockout in bladder cancer cells and analyze its effects on bladder cancer cells. This evidence concerns the gene MMP9 and urinary bladder carcinoma.